Quick Answer
Raphael Pharmaceutical Inc. reported Diluted EPS of $0.07 per share for fiscal year 2025.
Raphael Pharmaceutical Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.07 | -12.5% |
| 2024 | $0.08 | +0.0% |
| 2023 | $0.08 | -65.2% |
| 2022 | $0.23 | +64.3% |
| 2021 | $0.14 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.01 | +0.0% | -50.0% |
| June 30, 2025 | $0.02 | +100.0% | +0.0% |
| March 31, 2025 | $0.02 | -33.3% | +100.0% |
| September 30, 2024 | $0.01 | -75.0% | +0.0% |
| June 30, 2024 | $0.01 | -66.7% | -66.7% |
| March 31, 2024 | $0.03 | +50.0% | -25.0% |
| September 30, 2023 | $0.04 | -60.0% | +33.3% |
| June 30, 2023 | $0.03 | -40.0% | +50.0% |
- Raphael Pharmaceutical Inc. showed a decrease of -12.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Raphael Pharmaceutical Inc.’s diluted eps has declined by 50.0% (from $0.14 per share to $0.07 per share).
- The most recent figure is from Raphael Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: